Retour

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

News Clinical Study

ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings

GlobeNewswire Inc. • 07/05/2024 à 18:30:00
Annexon, Inc. Common Stock
Address: 1400 SIERRA POINT PARKWAY
Postal Code: 94005
City: BRISBANE
State: CA
Phone Number: (650)-822-5500
Website: https://www.annexonbio.com
Status: Active
Company Info

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

List Date2020-07-24
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001528115
Composite figiBBG007QVDFG2
Share Class figiBBG007QVDFH1
Market Cap400,147,710 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees70
Share Class Shares Outstanding92410000
Weighted Shares Outstanding92412866
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
4.384
4.37
4.655
4.89
4.875
Variance
0.41%
-3.98%
-3.42%
0.06%
-0.51%
Open
4.366
4.551
4.82
4.887
4.9
Highest
4.51
4.695
5.034
5.179
5.145
Lowest
4.51
4.695
5.008
5.16
5.128
History
PeriodVarhighestlowest
1 week
-10.53%
5.145
4.51
1 month
-2.6%
4.655
4.51
3 month
-19.82%
5.944
4.51
6 month
71.92%
2.66
2.27
1 year
-24.28%
6.0577
1.57
3 year
-78.08%
21.2696
1.57
5 year
-74.8%
19
1.57
10 year
-74.8%
19
1.57
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-07 2023-11-13 UNPUB
Assets 268,778,000 233,013,000 203,816,000 UNPUB
Current Assets 232,536,000 197,561,000 169,169,000 UNPUB
Current Liabilities 22,941,000 17,891,000 17,170,000 UNPUB
Equity 214,861,000 184,724,000 156,839,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 214,861,000 184,724,000 156,839,000 UNPUB
Liabilities 53,917,000 48,289,000 46,977,000 UNPUB
Liabilities And Equity 268,778,000 233,013,000 203,816,000 UNPUB
Noncurrent Assets 36,242,000 35,452,000 34,647,000 UNPUB
Noncurrent Liabilities 30,976,000 30,398,000 29,807,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-07 2023-11-13 UNPUB
Exchange Gains/Losses -5,000 -1,000 -2,000 UNPUB
Net Cash Flow 4,100,000 -30,506,000 19,545,000 UNPUB
Net Cash Flow, Continuing 4,105,000 -30,505,000 19,547,000 UNPUB
Net Cash Flow From Financing Activities 17,581,000 345,000 0 UNPUB
Net Cash Flow From Financing Activities, Continuing 17,581,000 345,000 0 UNPUB
Net Cash Flow From Investing Activities 19,517,000 5,531,000 47,838,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 19,517,000 5,531,000 47,838,000 UNPUB
Net Cash Flow From Operating Activities -32,993,000 -36,381,000 -28,291,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -32,993,000 -36,381,000 -28,291,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-07 2023-11-13 UNPUB
Comprehensive Income/Loss -38,521,000 -35,142,000 -32,434,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -38,521,000 -35,142,000 -32,434,000 UNPUB
Other Comprehensive Income/Loss -38,521,000 -35,142,000 -32,434,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-08 2023-08-07 2023-11-13 UNPUB
Basic Earnings Per Share -1 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -38,676,000 -35,188,000 -32,482,000 UNPUB
Income/Loss From Continuing Operations Before Tax -38,676,000 -35,188,000 -32,482,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -38,676,000 -35,188,000 -32,482,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -38,676,000 -35,188,000 -32,482,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -38,676,000 -35,188,000 -32,482,000 UNPUB
Operating Expenses 41,242,000 37,691,000 34,781,000 UNPUB
Operating Income/Loss -41,242,000 -37,691,000 -34,781,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-03-06
Assets 250,569,000 220,704,000 312,722,000 285,096,000
Current Assets 211,254,000 181,372,000 274,777,000 248,098,000
Current Liabilities 17,053,000 20,254,000 20,220,000 22,360,000
Equity 200,614,000 168,044,000 260,602,000 231,194,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 200,614,000 168,044,000 260,602,000 231,194,000
Liabilities 49,955,000 52,660,000 52,120,000 53,902,000
Liabilities And Equity 250,569,000 220,704,000 312,722,000 285,096,000
Noncurrent Assets 39,315,000 39,332,000 37,945,000 36,998,000
Noncurrent Liabilities 0 0 31,900,000 31,542,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-03-06
Exchange Gains/Losses 3,000 -6,000 -4,000 1,000
Net Cash Flow 37,985,000 -8,348,000 106,044,000 65,043,000
Net Cash Flow, Continuing 37,982,000 -8,342,000 106,048,000 65,042,000
Net Cash Flow From Financing Activities 19,000 113,000 122,668,000 122,908,000
Net Cash Flow From Financing Activities, Continuing 19,000 113,000 122,668,000 122,908,000
Net Cash Flow From Investing Activities 68,251,000 19,709,000 14,098,000 58,443,000
Net Cash Flow From Investing Activities, Continuing 68,251,000 19,709,000 14,098,000 58,443,000
Net Cash Flow From Operating Activities -30,288,000 -28,164,000 -30,718,000 -116,309,000
Net Cash Flow From Operating Activities, Continuing -30,288,000 -28,164,000 -30,718,000 -116,309,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-03-06
Comprehensive Income/Loss -35,373,000 -37,137,000 -35,021,000 -142,139,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -35,566,000 -37,203,000 -35,021,000 -142,139,000
Other Comprehensive Income/Loss 0 0 -35,021,000 -142,139,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-08 2022-11-03 2023-03-06
Basic Earnings Per Share -1 -1 -1 -3
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -35,373,000 -37,137,000 -35,054,000 141,947,000
Income/Loss From Continuing Operations Before Tax -35,373,000 -37,137,000 -35,054,000 141,947,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -35,373,000 -37,137,000 -35,054,000 -141,947,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -35,373,000 -37,137,000 -35,054,000 -141,947,000
Net Income/Loss Available To Common Stockholders, Basic -35,373,000 -37,137,000 -35,054,000 -141,947,000
Operating Expenses 35,426,000 37,409,000 36,069,000 145,599,000
Operating Income/Loss -35,426,000 -37,409,000 -36,069,000 -145,599,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-16 2021-11-09 2022-03-01
Assets 333,117,000 331,784,000 310,156,000 287,040,000
Current Assets 330,522,000 304,393,000 275,498,000 247,693,000
Current Liabilities 10,695,000 10,284,000 11,919,000 21,744,000
Equity 321,442,000 295,335,000 264,477,000 231,909,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 321,442,000 295,335,000 264,477,000 231,909,000
Liabilities 11,641,000 36,449,000 45,679,000 55,131,000
Liabilities And Equity 333,117,000 331,784,000 310,156,000 287,040,000
Noncurrent Assets 2,595,000 27,391,000 34,658,000 39,347,000
Noncurrent Liabilities 0 0 33,760,000 33,387,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-16 2021-11-09 2022-03-01
Exchange Gains/Losses -1,000 -1,000 -3,000 -5,000
Net Cash Flow -60,730,000 -107,081,000 -31,069,000 -192,556,000
Net Cash Flow, Continuing -60,729,000 -107,080,000 -31,066,000 -192,551,000
Net Cash Flow From Financing Activities 268,000 652,000 -73,000 1,795,000
Net Cash Flow From Financing Activities, Continuing 268,000 652,000 -73,000 1,795,000
Net Cash Flow From Investing Activities -37,581,000 -83,074,000 -1,278,000 -88,236,000
Net Cash Flow From Investing Activities, Continuing -37,581,000 -83,074,000 -1,278,000 -88,236,000
Net Cash Flow From Operating Activities -23,416,000 -24,658,000 -29,715,000 -106,110,000
Net Cash Flow From Operating Activities, Continuing -23,416,000 -24,658,000 -29,715,000 -106,110,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-16 2021-11-09 2022-03-01
Comprehensive Income/Loss -26,060,000 -31,294,000 -35,608,000 -130,426,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -26,032,000 -31,276,000 -35,608,000 -130,426,000
Other Comprehensive Income/Loss 0 0 -35,608,000 -130,426,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-17 2021-08-16 2021-11-09 2022-03-01
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -26,060,000 -31,294,000 -35,598,000 -130,323,000
Income/Loss From Continuing Operations Before Tax -26,060,000 -31,294,000 -35,598,000 -130,323,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -26,060,000 -31,294,000 -35,598,000 -130,323,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -26,060,000 -31,294,000 -35,598,000 -130,323,000
Net Income/Loss Available To Common Stockholders, Basic -26,006,000 -31,294,000 -35,598,000 -130,323,000
Operating Expenses 26,148,000 31,373,000 35,680,000 130,713,000
Operating Income/Loss -26,148,000 -31,373,000 -35,680,000 -130,713,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-16 2021-03-25
Assets UNPUB UNPUB 375,614,000 355,946,000
Current Assets UNPUB UNPUB 373,575,000 354,011,000
Current Liabilities UNPUB UNPUB 8,988,000 10,622,000
Equity UNPUB UNPUB 365,479,000 344,278,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 365,479,000 344,278,000
Liabilities UNPUB UNPUB 10,135,000 11,668,000
Liabilities And Equity UNPUB UNPUB 375,614,000 355,946,000
Noncurrent Assets UNPUB UNPUB 2,039,000 1,935,000
Noncurrent Liabilities UNPUB UNPUB 1,147,000 1,046,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-16 2021-03-25
Exchange Gains/Losses UNPUB UNPUB 4,000 9,000
Net Cash Flow UNPUB UNPUB 245,921,000 224,625,000
Net Cash Flow, Continuing UNPUB UNPUB 245,917,000 224,616,000
Net Cash Flow From Financing Activities UNPUB UNPUB 259,781,000 360,876,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 259,781,000 360,876,000
Net Cash Flow From Investing Activities UNPUB UNPUB -276,000 -83,164,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -276,000 -83,164,000
Net Cash Flow From Operating Activities UNPUB UNPUB -13,584,000 -53,087,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -13,584,000 -53,087,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-16 2021-03-25
Comprehensive Income/Loss UNPUB UNPUB -15,634,000 -63,409,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -15,634,000 -63,409,000
Other Comprehensive Income/Loss UNPUB UNPUB -15,634,000 -63,409,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-16 2021-03-25
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -15,638,000 -63,412,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -15,637,000 -63,412,000
Income Tax Expense/Benefit UNPUB UNPUB 1,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -15,638,000 -63,412,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -15,638,000 -63,412,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -22,002,000 -70,336,000
Operating Expenses UNPUB UNPUB 15,585,000 63,469,000
Operating Income/Loss UNPUB UNPUB -15,585,000 -63,469,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 6,364,000 6,924,000
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 6,364,000 6,924,000
Revenues UNPUB UNPUB 0 0
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ANNX240517P00016000 OPASPS Put American 100 16 BATO 2024-05-17
O:ANNX240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:ANNX240517P00014000 OPASPS Put American 100 14 BATO 2024-05-17
O:ANNX240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:ANNX240517P00011000 OPASPS Put American 100 11 BATO 2024-05-17
O:ANNX240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:ANNX240517P00009000 OPASPS Put American 100 9 BATO 2024-05-17
O:ANNX240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:ANNX240517P00006000 OPASPS Put American 100 6 BATO 2024-05-17
O:ANNX240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:ANNX240517P00004000 OPASPS Put American 100 4 BATO 2024-05-17
O:ANNX240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:ANNX240517C00016000 OCASPS Call American 100 16 BATO 2024-05-17
O:ANNX240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:ANNX240517C00014000 OCASPS Call American 100 14 BATO 2024-05-17
O:ANNX240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:ANNX240517C00011000 OCASPS Call American 100 11 BATO 2024-05-17
O:ANNX240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:ANNX240517C00009000 OCASPS Call American 100 9 BATO 2024-05-17
O:ANNX240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:ANNX240517C00006000 OCASPS Call American 100 6 BATO 2024-05-17
O:ANNX240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:ANNX240517C00004000 OCASPS Call American 100 4 BATO 2024-05-17
O:ANNX240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:ANNX240419P00004000 OPASPS Put American 100 4 BATO 2024-04-19
O:ANNX240419C00004000 OCASPS Call American 100 4 BATO 2024-04-19
O:ANNX240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:ANNX240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:ANNX240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:ANNX240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:ANNX240419P00016000 OPASPS Put American 100 16 BATO 2024-04-19
O:ANNX240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:ANNX240419P00014000 OPASPS Put American 100 14 BATO 2024-04-19
O:ANNX240419P00011000 OPASPS Put American 100 11 BATO 2024-04-19
O:ANNX240419P00009000 OPASPS Put American 100 9 BATO 2024-04-19
O:ANNX240419P00006000 OPASPS Put American 100 6 BATO 2024-04-19
O:ANNX240419C00016000 OCASPS Call American 100 16 BATO 2024-04-19
O:ANNX240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:ANNX240419C00014000 OCASPS Call American 100 14 BATO 2024-04-19
O:ANNX240419C00011000 OCASPS Call American 100 11 BATO 2024-04-19
O:ANNX240419C00009000 OCASPS Call American 100 9 BATO 2024-04-19
O:ANNX240419C00006000 OCASPS Call American 100 6 BATO 2024-04-19
O:ANNX240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:ANNX240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ANNX240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:ANNX240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:ANNX240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ANNX240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:ANNX240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:ANNX240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:ANNX240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:ANNX240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ANNX240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:ANNX240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:ANNX240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ANNX240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:ANNX240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:ANNX240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ANNX240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:ANNX240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:ANNX240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ANNX240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:ANNX240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:ANNX240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:ANNX240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ANNX240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ANNX240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ANNX240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:ANNX240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:ANNX240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ANNX240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ANNX240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:ANNX231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:ANNX231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:ANNX231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:ANNX231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:ANNX231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:ANNX231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:ANNX231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:ANNX231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:ANNX231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:ANNX231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:ANNX231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:ANNX231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:ANNX231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:ANNX231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:ANNX231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:ANNX231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:ANNX231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:ANNX231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:ANNX231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:ANNX231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:ANNX231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:ANNX231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:ANNX230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:ANNX230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:ANNX230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:ANNX230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:ANNX230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:ANNX230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:ANNX230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:ANNX230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:ANNX230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:ANNX230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:ANNX230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:ANNX230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Changes in company's own shares
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 2d ago
Stocks Earnings Releases and Operating Results
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024
GlobeNewswire Inc. • 6d ago
Calendar Calendar of Events
Annexon Biosciences to Present at the Bank of America Health Care Conference
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Bank of America Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT.
GlobeNewswire Inc. • 1w ago
News Clinical Study
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings
GlobeNewswire Inc. • 1w ago
Stocks Changes in company's own shares
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 1mo ago
News News
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.
Zacks Investment Research • 1mo ago
News News
What Makes Annexon (ANNX) a New Buy Stock
Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • 1mo ago
News News
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • 1mo ago
Stocks Earnings Releases and Operating Results
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024
GlobeNewswire Inc. • 1mo ago
stocks Earnings Releases and Operating Results
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024
GlobeNewswire Inc. • 1mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT